Viropharma Inc

Viropharma — Investor Day (September 2012)

167 slides from Viropharma's investor day presentation, Sep 21, 2012

  1. Slide 1: Broadening Horizons: 2012 Investor Day

    Broadening Horizons 2012 ViroPharma Incorporated Investor Day September 21, 2012

  2. Slide 2: Introduction

    Introduction Vincent Milano Chief Executive Officer 2

  3. Slide 3: Forward-looking statements

    This presentation contains certain forward-looking statements, including statements regarding our financial guidance for 2012 and beyond, our projected financial condition, the rate of future growth and the development and commercialization status and prospects of certain of our products and product

  4. Slide 4: The ViroPharma Story

    The ViroPharma Story 4 PEOPLE PATIENTS PHYSICIANS EMPLOYEES SHAREHOLDERS GROWTH DIVERSIFICATION EXECUTION UPSIDE Providing Hope for People Suffering from Rare & Life-Threatening Diseases

  5. Slide 5: Today's Agenda

    Today’s Agenda North American Operations EU Commercial Operations 15 Minute Break Approximately 10:15 – 10:30 AM C1-INH Potential Therapeutic Uses Subcutaneous Cinryze® Maribavir VP-20621 NTCD Capital Structure and Long-Range Model Meeting Adjourned – Approximately 12:45 PM

  6. Slide 6: North American Operations

    North American Operations Paul Firuta Vice President & General Manager, Americas 6

  7. Slide 7: Goals and Objectives

    Goals and Objectives 7 N.A. Peak Revenue >$600 Million (IV/HAE Only) Cinryze® Post Orphan Exclusivity Base Cinryze Business Competitive Landscape

  8. Slide 8: Agenda

    Agenda 8 Cinryze® Brand Strategies and Performance Customer Insights Review Changes in Competitive Landscape Cinryze IV—Post Orphan Exclusivity Geographic Expansion

  9. Slide 9: Strategic Objectives in HAE Market

    Strategic Objectives in HAE Market Raise awareness of the severity and impact of HAE amongst allergists and other targeted HAE-treating specialists Increase diagnosis rate of HAE Educate clinicians and patients about the benefits of prevention and establish Cinryze as the preferred prophylactic ther

  10. Slide 10: Increase Diagnosis: Accomplishments

    Increase Diagnosis (Dx): Accomplishments 10 A. ViroPharma 2012 Market Research 100% growth in Dx 2006 to 2012 Estimated over 7,000 Dx patients in North America CinryzeSolutions™ known patient population >1,700 60% Rx are Allergy / Immunology 40% other specialties 60% Rx in CinryzeSolutions coming fr

  11. Slide 11: Increase Enrollment: Accomplishments

    Ended Q2/12 maintaining >820 patients @ 1.8 doses per week Approximately 1/3 of patients who initiated Cinryze therapy in 2012 have been diagnosed in last 3 years 3rd quarter 2012 is the 2nd largest Rx quarter since Q3 2009 Increase Enrollment: Accomplishments Cinryze® Sales Force & CinryzeSolutions

  12. Slide 12: Maintain Patients On Therapy: Accomplishments

    Maintain Patients On Therapy: Accomplishments 12 Less than 5% of patients discontinue Cinryze® prophylactic therapy 78% of patients infuse in home 88% satisfaction with CinryzeSolutions program 94% satisfaction with CinryzeSolutions™ Care Coordinator CinryzeSolutions Patient Service Center Focused o

  13. Slide 13: Growth in Expected North America Peak Sales

    >$600 million North America $450 million peak sales 2 years ago Execution Has Delivered Progressive Growth in Expected Peak Sales 13 Strategies and tactics performance exceed expectations Significant opportunity still exists in Allergy / Immunology and other specialties Key areas of focus for Commer

  14. Slide 14: CinryzeSolutions Programs

    14 CinryzeSolutions™ Programs

  15. Slide 15: CinryzeSolutions Programs

    Access, resources, and support every step of the way CinryzeSolutions™ Programs 15

  16. Slide 16: Customer Insights

    Customer Insights Better Understanding of the Market 16

  17. Slide 17: Physician Reported Findings 2012

    Physician Reported Findings 2012 17 More than 50% of Allg/Immun surveyed intend to increase utilization of Cinryze® Significant decrease in physician satisfaction with anabolic steroids and FFP Physicians across all specialties are highly satisfied with Cinryze for prophylactic treatment No reported

  18. Slide 18: Physician Reported Findings 2012

    Physician Reported Findings 2012 18 Anabolic steroids and FFP are 71% more likely to be prescribed in other specialties Allg/Immun still likely to prescribe anabolic steroids 33% of the time Cinryze® is now more likely be prescribed than anabolic steroids in Allg/Immun Significant progress in Allg/I

  19. Slide 19: Months of Consistent Rx Generation

    35 Months of Consistent Rx Generation Post Launch Phase 19 B. ViroPharma Inc. CINRYZESolution Database August 28, 2012 Months Number of SRF’s

  20. Slide 20: Key Market Factors

    Key Market Factors 20 Recent clinical experience with danazol is not as favorable from an efficacy perspective Increased awareness regarding risk of long-term safety issues with danazol Increasing awareness of newer treatment options A. ViroPharma 2012 Market Research

  21. Slide 21: Competitive Landscape Changing

    Competitive Landscape Changing 21

  22. Slide 22: New Treatment Guidelines

    New Treatment Guidelines Attenuated androgens and C1-INH should be considered for routine prevention in HAE patients with > 1 – 2 attacks/month Attenuated androgens are not identified as first-line therapy Maximum recommended daily dose for danazol = 200 mg/day Attenuated androgens are not recommend

  23. Slide 23: Key Take Away: Competitive Landscape

    Key Take Away: Competitive Landscape 25 Efficacy of danazol is beginning to be questioned Adherence to the new clinical treatment guidelines would clearly limit the use of anabolic steroids Cinryze® is well positioned as a safe and efficacious prophylactic therapy Opportunity to educate managed care

  24. Slide 24: Post Cinryze IV Orphan Exclusivity October 2015

    Post Cinryze® IV Orphan Exclusivity October 2015 26

  25. Slide 25: The Exclusivity Proposition

    The Exclusivity Proposition 27 Orphan Market Exclusivity 7 Years +5 Years HCR Data Exclusivity US 2008 2020 2015 Today

  26. Slide 26: Low Risk of 2nd Approved IV C1-INH Prophylactic

    Low Risk of 2nd Approved IV C1-INH Prophylactic Indication 2015 to 2020 2nd approved IV C1-INH Prophylaxis HAE Therapy Post-2015 Ethical Issues with Trial Design Patient Recruitment will be Challenging Phase III Double Blinded Placebo Controlled Trial No CI Indicating Phase III Trial for IV Prophyla

  27. Slide 27: Ultra Orphan Drug Market Analog: Alpha-1 Antitrypsin

    Market Background and Data Ultra Orphan Drug Market Analog Alpha-1 Antitrypsin 29 Key Insights The 1st entrant in class maintaining the market value leadership despite one competitor with better profile The originator product sales grew year-over-year post exclusivity period Total market value incre

  28. Slide 28: Key Take Away

    Key Take Away 30 Low risk of a new IV C1-INH prophylactic entrant post Cinryze® Orphan Exclusivity Key to maintaining our position in the market is: Patient Service Model – CinryzeSolutions™ Based on Alpha-1 market analog: Alpha-1 market grew Innovator product maintained revenue Innovator product co

  29. Slide 29: Geographic Expansion

    Geographic Expansion 31

  30. Slide 30: Other Geographic Market Opportunities

    Other Geographic Market Opportunities 32 Canada – filed and has a Priority Review Anticipated regulatory decision in Q4 2012 Market is estimated to be 1/10th of US Market opportunity will depend on pricing Latin America Evaluating markets Working with KOLs and potential distribution partners to unde

  31. Slide 31: Closing Remarks North America

    Closing Remarks 33 North America Peak Revenue $600 million + IV / HAE Only Deliver consistent patient enrollment & outstanding patient services Implement new consensus treatment guidelines Low risk of a 2nd IV C1-INH post Orphan Exclusivity Expansion into other geographies Subcutaneous formulation O

  32. Slide 32: To the Makers of Cinryze

    To the Makers of Cinryze, To the owners, operators, employees, producers and everybody who has anything to do with the production of CINRYZE, I have no words that can express my gratitude for the care that has been given to me in the past 6 months. I’ve had only one minor HAE attack after starting C

  33. Slide 33: ViroPharma in Europe

    ViroPharma in Europe Thierry Darcis, MD Vice President & General Manager, Europe 35

  34. Slide 34: ViroPharma Europe in a Nutshell

    ViroPharma Europe in a Nutshell 36 One Team Three Launched Brands Delivering Innovative Disease Management Solutions

  35. Slide 35: ViroPharma Europe – It All Fits Together

    ViroPharma Europe – It All Fits Together Serious, debilitating diseases Clear medical needs Overlooked markets Lagging in innovation Established therapeutic areas Vying for market share Products which make a difference for patients Introducing new “gold standards” Highly specialized markets Competin

  36. Slide 36: ViroPharma Europe – How We Deliver

    ViroPharma Europe – How We Deliver Deep understanding of Disease Health care providers Patients and carers Developing meaningful insights on Treatment paradigms “Disease community” Selecting the highest medical need segments Including relevant stakeholders Deploying 2 key initiatives at a time Scien

  37. Slide 37: Is the Model Working?

    ViroPharma Europe – Is the Model Working? 39 Launched Cinryze® in October 2011; Buccolam® in December 2011; Plenadren® in September 2012 Cinryze – Over 60 patients on long term prevention / treatment on demand Buccolam – ~50% of Primary Care Trusts in UK are switching over to Buccolam. Positive opin

  38. Slide 38: European Roll-Out of Cinryze

    European Roll-Out of Cinryze 40 This presentation includes information about a product which is approved for indications in Europe which are not approved in the United States. This information is for investor purposes only, and should not be relied upon by health care professionals. It is intended t

  39. Slide 39: HAE in Europe—An Established Market

    HAE in Europe—An Established Market 41 Overall epidemiology similar to that of the US (~12,500 patients) Differences exist at individual country level: Awareness, diagnosis rates, and treatment approaches HAE management by health care structures Treating specialists Current paradigm is still acute t

  40. Slide 40: HAE in Europe Prior to Cinryze: Burden of Illness

    HAE in Europe Prior to Cinryze® Burden of Illness Study Confirms Needs and Paradigm 42 First multi-country, cross-sectional survey completed by patients partnered with KOLs and advocacy groups Excitement in the HAE community (KOLs and advocacy groups) 59% of patients had >1 attack/month The majority

  41. Slide 41: HAE in Europe—Burden of Illness Study

    HAE in Europe—Burden of Illness Study Confirms Needs and Paradigm 43 Overall impact (0 lowest; 10 highest) Daily life is impacted regardless of attack location Patients experience substantial detriments in career and educational advancement due to HAE EAACI Geneva 2012

  42. Slide 42: HAE Prevention – Limited Prophylactic Competition in Europe

    HAE Prevention – Limited Prophylactic Competition in Europe 44 Product Company Acute Prevention Use in HAE Prevention ( ) Cinryze® ViroPharma ? ? Only C1-INH product approved for a Prevention indication in EU Berinert CSL-B ? X Prevention not in label; has not been studiedUsed as treatment on demand

  43. Slide 43: HAE Acute Therapies—A Highly Competitive Market

    HAE Acute Therapies—A Highly Competitive Market 45 Product Company Acute Prevention EU Regulatory Status Cinryze® ViroPharma ? ? Central EMA approval Berinert CSL-B ? X Approved in Europe through Mutual Recognition Program Firazyr Shire ? X Centrally approved by EMA Pan-EU launch in 2009 Rhucin Phar

  44. Slide 44: HAE Prevention – The Future of HAE in Europe

    HAE Prevention – The Future of HAE in Europe 46 Prevention of HAE attacks is more established than commonly thought 30% to 60% of current patients managed by prevention Until Cinryze® launch, the main “prophylactic products” included: Androgens (danazol) Tranexamic acid With Cinryze launch, preventi

  45. Slide 45: Cinryze—The European Product has Passed Major Hurdles

    Cinryze®—The European Product has Passed Major Hurdles 47 Obtained EMA centralized approval in June 2011 with broad label Switzerland – Final stages of the regulatory process Launched and reimbursed in: Germany, Spain; UK; Denmark; Iceland Average ex-factory price per dose ca. € 1,400, in line with

  46. Slide 46: Geographical Rollout of Cinryze

    Geographical Rollout of Cinryze® 48 Austria (2013) Czech Rep. (2013) Denmark France Germany Hungary (2013) Iceland Ireland Italy (2013) Norway Spain Sweden Switzerland (2013) UK Belgium & Netherlands (via Sanquin) Israel (2013) Austria Czech Rep. Denmark Germany Greece Hungary Ireland Italy Norway P

  47. Slide 47: 2010 Rollout Strategy

    2010 Rollout Strategy—The Original Strategy Remains Valid 49 Patient visits GP / A&E to discuss symptoms Patient takes the drug Origination Diagnosis Treatment Choice Brand Choice 1st Administration Compliance Persistence Patient complies with prescription Patient does not comply with prescription H

  48. Slide 48: Choosing Cinryze in Europe

    Choosing Cinryze® in Europe First priority of rollout: Switch prescribers from Berinert, danazol and tranexamic acid to Cinryze for preventative HAE management 50 1 Capture market share “own the prevention market” $3.1M net sales in first half of 2012 More than 60 patients in Europe have started Cin

  49. Slide 49: Preventative HAE Management as Gold Standard

    Preventative HAE Management as Gold Standard The second priority of the Cinryze® rollout will be to firmly establish the concept of preventative HAE management 51 2 “The ability to prevent attacks can provide relief to many patients” (Dr. Emel Aygören^Pürsün) “Routine prevention can help to improve

  50. Slide 50: Encouraging Compliance

    Encouraging Compliance The third priority of the Cinryze® rollout will be to make using the product as convenient as possible for the patient, including future development of subcutaneous formulation 52 3 Libertas+ (homecare services similar to US Ryze Above®) successfully rolled-out in Germany and

  51. Slide 51: Cinryze—One-Stop Shop Solution for HAE Management

    Cinryze®—Possibility of a One-Stop Shop Solution for HAE Management in Europe HAE epidemiology similar to that of US Prior prevention options not satisfying patient needs Cinryze is the only HAE product with a broad label including acute and preventative label and self-administration Cinryze has the

  52. Slide 52: European Launch of Plenadren

    European Launch of Plenadren® Dirk De Rijdt Director & Brand Leader, Europe 54 This presentation includes information about a product which is not approved in the United States. This information is for investor purposes only, and should not be relied upon by health care professionals. It is intended

  53. Slide 53: Adrenal Insufficiency—Disease & Epidemiology in Europe

    Adrenal Insufficiency—Disease & Epidemiology in Europe Adrenal Insufficiency (AI) is an Orphan Disease affecting ~ 400 patients per million inhabitants (range 80,000 – 167,000 pts in EU) Adrenal Insufficiency has two main causes: Primary AI – Addison’s Disease Secondary AI – associated with hypopitu

  54. Slide 54: Glucocorticoid Replacement – Competition Products

    AI in Europe—Glucocorticoid Replacement – Competition Products 56 Currently branded products account for 26% of the market, with generic products accounting for the remaining 74% As many of the branded products were launched over 40 years ago, they are now priced and treated as generic products Prod

  55. Slide 55: Adrenal Insufficiency – Significant Unmet Need

    57 Adrenal Insufficiency – Significant Unmet Need

  56. Slide 56: The Circadian Rhythm—Un-physiological Timing and Dose of HC

    The Circadian Rhythm—The Un-physiological Timing and Dose of HC 58 Johannsson et al. J Clin Endocrinol Metab. 2012;97:473-81 1.Plat et al. 1999; 2.Gangwisch 2009; 3. Matthews et al. 2006 4. Garcia-Borreguero et al. 2000; 5. Vgontzas et al. 2001 Clock time 08.00 12.00 16.00 24.00 0 200 400 600 800 Co

  57. Slide 57: Plenadren—Immediate and Extended Release Action

    Plenadren®—Immediate and Extended Release Action 59 Rapid release part together with controlled release part mimics diurnal variation Night time cortisol-free interval Reproducible absorption and high bioavailability Once-daily administration Two strengths: 20mg and 5mg Plenadren’s “dual action” ach

  58. Slide 58: Plenadren vs. HC (TID)—Clinical Program Conclusions

    Plenadren® vs. HC (TID)—Conclusions from the Clinical Program 60 Plenadren resulted in: Increased cortisol exposure during the first hours after intake in the morning Reduced exposure in the afternoon and evening, avoiding the last two peaks during TID Reduced total exposure over the 24-hour period

  59. Slide 59: Plenadren—In Summary

    Plenadren®—In Summary 61 Since ViroPharma’s acquisition of Plenadren: Manufacturing to meet 24-36 month demand in place Shelf-life increased to 36 months Dedicated commercial capabilities built in preparation for launches P&R filings and launches in further countries under preparation Average price

  60. Slide 60: Plenadren—Rollout Strategy

    Plenadren®—Rollout Strategy 62 Patient visits GP to discuss symptoms Patient is satisfied Origination Diagnosis Treatment Choice Brand Choice Routine Follow-up Visits Long-term Persistence Endocrinologist chooses between natural or synthetic products Patient is not satisfied Endocrinologist diagnose

  61. Slide 61: Switching Patients with Unmet Needs

    1 Switching Patients with Unmet Needs First priority of Plenadren® rollout: Switch patients with poor disease and metabolic control and issues with compliance during conventional treatment 40% to 60% of currently treated primary and secondary AI patients are not well controlled or have difficulties

  62. Slide 62: Achieving Short-term Persistence

    Achieving Short-term Persistence Plenadren’s® success depends on improving treatment habits; clear guidance to physicians, nurses, and patients; better patient-physicians interactions; and patient education Plenadren offers the opportunity of improved compliance and better management during episodes

  63. Slide 63: Circadian Glucocorticoid Replacement as 1st Choice

    “Circadian” Glucocorticoid Replacement as 1st Choice Treatment for AI patients Through the initial use of Plenadren® in high medical need patients, health care providers supported by patient associations will gain experience and confidence to use Plenadren in a broader AI population, including newly

  64. Slide 64: Plenadren—Can Become the Gold Standard Treatment of AI

    Plenadren®—Can Become the Gold Standard Treatment of AI AI is a serious disease characterized by increased mortality in the short (adrenal crisis) and long-term (metabolic consequences); difficult to manage by patients and physicians Plenadren has been designed to better mimic the normal physiologic

  65. Slide 65: European Roll-Out of Buccolam

    European Roll-Out of Buccolam® Arun Mistry, MD Senior Director, Medical Affairs Europe 67 This presentation includes information about a product which is not approved in the United States. This information is for investor purposes only, and should not be relied upon by health care professionals. It

  66. Slide 66: Convulsive Seizures—Disease & Epidemiology in Europe

    Causes and clinical manifestations Convulsive Seizures (CS)—Disease & Epidemiology in Europe 68 Genetic predisposition Acquired brain damage Increased risk of attacks Epilepsy Abnormal and excessive brain neuron discharge Unspecific provoking factors Specific provoking factors Altered consciousness

  67. Slide 67: CS—The Most Common Serious Brain Disorder

    CS—The Most Common Serious Brain Disorder 69 Epilepsy: 5% of people can expect ? 1 seizure during lifetime In Europe an estimated 700,000 suffers from this condition between 3 months and less than 18 years of age Important to manage both acute and chronic elements of epilepsy A well-know condition P

  68. Slide 68: CS in Europe—Available Products

    CS in Europe—Available Products 70 Generic name Route of administration Dosage Available for clinical use Diazepam Rectal 0.2-0.5 mg/kg Licensed in most countries (eg. Stesolid® in Spain, Miconoan® in Italy) Midazolam (hydrochloride) Buccal Age-specific dosing EU-wide license (Buccolam®) Midazolam (

  69. Slide 69: Acute Management of CS—An Overlooked Medical Need

    Acute Management of CS—An Important, Overlooked Medical Need 71 ViroPharma’s “PERFECT Initiative” has highlighted many of these issues While research has focused on the chronic treatment of CS, acute management of the condition has not evolved in decades and still relies on IRD (Intra Rectal Diazepa

  70. Slide 70: PERFECT Initiative

    PERFECT is a ViroPharma-funded initiative, guided by a steering committee of leading clinical experts and patients associations 72 “What happens when a child or adolescent has a prolonged, acute, convulsive seizure in the community?”

  71. Slide 71: Preliminary Conclusions

    Preliminary Conclusions 73 IRD fails community and carers. Acute management of CS requires a different and more convenient benzodiazepine

  72. Slide 72: Buccolam – 1st Product Approved Through EMA PUMA

    Buccolam® – 1st Product Approved Through the EMA “PUMA” (2011) 74 4 age-specific unit-dose pre-filled oral syringes (4 tubes per carton) Single dose for simplified management by carer Buccolam vs. IRD Several clinical studies have investigated the efficacy and safety of buccal midazolam Conclusions

  73. Slide 73: Buccolam – Rollout Strategy

    Buccolam® – Rollout Strategy 75 Patient visits GP/Emergency Care/Neurologist after first seizure Patient/Parent is satisfied Origination Diagnosis Treatment Choice Brand Choice Routine follow-up visits Long-term Persistence Neurologist chooses between no acute management (majority) or IRD (mostly),

  74. Slide 74: Build Buccolam as Gold Standard for Acute CS Management

    Build Buccolam® as Gold Standard for Acute CS Management Adoption by the reference centers KOL advocacy is critical to the conversion to Buccolam from other treatments Focus on the top 5-10% of accounts in each market Buccolam listed in formularies and used in hospital and for out-patients Drive the

  75. Slide 75: Switch Patients with Unmet Needs

    Switch Patients with Unmet Needs Utilize advocates from reference centers to educate physicians closest to patients on available acute seizure treatment options Work closely with patient advocacy groups to provide education on management of acute CS Add Buccolam to chronic therapy plan as acute seiz

  76. Slide 76: Buccolam – In Summary

    Buccolam® – In Summary Obtained EMA centralized approval in September 2011 Launched and reimbursed in UK and Germany; NPP availability in France and Spain Obtained an average ex-factory price per carton of ~€83 $1.8 M net sales in first half of 2012 Pricing & reimbursement process on-going in furthe

  77. Slide 77: Buccolam – Potential Standard of Care for Acute CS

    Buccolam® – Has Potential to be Standard of Care for Acute Management of CS Patients, carers, and doctors are not satisfied with the current acute seizure management practices and current IRD solution Buccolam unique profile meets clinical and social needs of patients and carers Buccolam is cost-sav

  78. Slide 78: ViroPharma Europe – Conclusions

    ViroPharma Europe – Conclusions 80 Differentiated brands Bringing innovation to patients and carers Exciting products for patients, physicians, and ViroPharma Peak potential: $300-500 million Focused on customers Superior commercialization capabilities Broad geographical reach Scalable

  79. Slide 79: Break

    15 Minute Break Refreshments and Snacks Please Return to Reconvene at 10:45 AM 81

  80. Slide 80: C1 Inhibitor: Potential New Therapeutic Uses

    C1 Inhibitor: Potential New Therapeutic Uses Jeffrey M. Dayno, MD Vice President, Global Medical Affairs 82

  81. Slide 81: The Opportunity

    The Opportunity Life cycle management: maximizing the value of the C1 Inhibitor franchise through new data and new indications C1 Inhibitor: platform development opportunity Greater understanding of the evolving science Intersection of the science and commercial opportunities Update on progress to d

  82. Slide 82: Identifying New Clinical Targets

    Identifying New Clinical Targets 84 Patient populations C1-INH MOA Disease pathophysiology

  83. Slide 83: Life Cycle Management

    Life Cycle Management 85 Unmet Medical Need Commercial Opportunity Product Profile

  84. Slide 84: Mechanism of Action of C1 Inhibitor

    Mechanism of Action of C1 Inhibitor 86 Biochemical function Biological effect Potential therapeutic effect Inhibition of C1r, C1s, MASPs Inhibition complement activation Anti-inflammatory Inhibition of factor XIIa and kallikrein Inhibition contact activation Anti-inflammatory Inhibition of factor XI

  85. Slide 85: Diseases Involving the Complement System

    Diseases Involving the Complement System 87 Ricklin D and Lambris JD. 2007

  86. Slide 86: Current Approach

    Current Approach 88 Refined thinking regarding potential clinical targets Informed by pre-clinical data from current Investigator Initiated Studies (IIS) Ongoing discussions with experts in Complement research Engagement with clinical opinion leaders in various medical subspecialties Prioritizing op

  87. Slide 87: Goals of an IIS Program

    Goals of an IIS Program 89 Provide a mechanism to support independent, investigator initiated research to: Advance clinical knowledge of different disease states, patient populations Further the understanding of the efficacy & safety of a therapeutic product in these disease states & patient populat

  88. Slide 88: Current Preclinical IIS Studies

    Current Preclinical IIS Studies 90 Study Status Experimental Autoimmune Encephalomyelitis (EAE): mouse model of Multiple Sclerosis Cardiff University Phase 1 (acute EAE) completed; beginning Phase 2 study (chronic EAE) Model of Type 1 Diabetes MellitusBIDMC Harvard Project 70% completed – anticipate

  89. Slide 89: Acute EAE: Preliminary Data

    Acute EAE: Preliminary Data 91 * * Treatment Regimen: 0.2ml of 100U/ml (32mg/ml) SC on alternate days, from day 8 With permission, Paul Morgan, Cardiff University

  90. Slide 90: Liver IRI: Preliminary Data

    Liver IRI: Preliminary Data Mouse model of liver ischemia reperfusion injury in setting of tumor resection, transplantation Hepatic artery clamped for 30 minutes 5 minutes prior to reperfusion Cinryze® administered vs. placebo (control) Results (at 24 hours): Control mice: ALT (liver function enzyme

  91. Slide 91: Cinryze Inhibits All Pathways of Complement Activation

    Cinryze: Inhibits All 3 Pathways of Complement Activation PNH others Ischemia Reperfusion Antibody Diseases ViroPharma, data on file

  92. Slide 92: C1-INH IIS Strategic Framework

    C1-INH IIS Strategic Framework Neuroimmunology Neuromyelitis Optica (NMO; Devic’s Syndrome) Myasthenia Gravis Guillain-Barré disease (AIDP); CIDP Multiple Sclerosis Hematologic diseases Autoimmune Hemolytic Anemia (AIHA) Paroxysmal Nocturnal Hemoglobinuria (PNH) Hemolytic Uremic Syndrome (HUS) Angio

  93. Slide 93: Current Clinical IIS Studies

    Current Clinical IIS Studies 95 Study Status RNAi markers in HAEJohns Hopkins Subject recruitment; blood sample collection Treatment of acute exacerbations in patients with Neuromyelitis Optica (NMO)Johns Hopkins Study start anticipated Q4 2012 Autoimmune Hemolytic Anemia (AIHA)AMC, Univ. of Amsterd

  94. Slide 94: Neuromyelitis Optica (NMO)

    Neuromyelitis Optica (NMO) 96 Inflammatory disease of the CNS that selectively attacks the optic nerves and spinal cord Prevalence: 1 – 3/100,000 Unique among the inflammatory demyelinating CNS diseases Associated with circulating IgG auto-antibodies against the astrocyte water channel protein aquap

  95. Slide 95: Autoimmune Hemolytic Anemia (AIHA)

    Autoimmune Hemolytic Anemia (AIHA) 97 Autoimmune disease involving auto-antibodies directed toward RBC surface antigens leading to accelerated destruction (hemolysis) Annual incidence: 1 – 3/100,0001 Two main types Warm AIHA: 70 – 80 % of cases (anti-RBC IgG > IgA, IgM) Cold AIHA (cold agglutinin sy

  96. Slide 96: Update on ViroPharma Sponsored Studies

    Update on ViroPharma Sponsored Studies 98 Antibody Mediated Rejection (AMR) in setting of renal transplant Approximately half of study cohort enrolled Anticipate study completion 4Q2013 Findings to be published Delayed Graft Function (DGF) reprioritized as a potential IIS study Laboratory study of P

  97. Slide 97: Summary

    Summary C1 Inhibitor: platform development opportunity Evolving science and greater understanding of complement-mediated disorders Emerging pre-clinical data informing potential new clinical targets More focused, mechanism-based approach Refinement of overall development strategy Broadening the hori

  98. Slide 98: Subcutaneous Administration of C1 INH

    Subcutaneous Administration of C1 INH Steven Gelone, PharmD Vice President, Clinical Development 100

  99. Slide 99: ViroPharma 2012 Goals

    VIROPHARMA 2012 GOALS PATIENTS LEGAL REGULATORY/QUALITY BD SALES & MARKETING MANAGED MARKETS TECH OPS CCOM MEDICAL AFFAIRS DEVELOPMENT FINANCE IT HUMAN RESOURCES VIROPHARMA INCORPORATED

  100. Slide 100: Quote: Ralph Waldo Emerson

    Do not go where the path may lead, go instead where there is no path and leave a trail. Ralph Waldo Emerson

  101. Slide 101: Prevention of AE Attacks with Cinryze

    Prevention of AE Attacks with CINRYZE has Transformed the Lives of Many Patients with HAE

  102. Slide 102: Quote: Robert Frost

    Two roads diverged in a wood, and I- I took the one less traveled by, And that has made all the difference. Robert Frost

  103. Slide 103: Complacency Kills

    Complacency Kills!!! “We shall have no better conditions in the future if we are satisfied with all those which we have at present.” -Thomas Edison

  104. Slide 104: Why SC Administration of Cinryze?

    Why SC Administration of CINRYZE? 1) More convenient option for HAE patients Route of administration Advantages Disadvantages Intravenous Precise control of dose and administration rate Rapid exposure Potential for reducing injection site reactions for irritating agents Minimal volume constraints (1

  105. Slide 105: The Arithmetic of AE Attacks

    Why SC Administration Of CINRYZE? The “Arithmetic” of AE Attacks Insufficient Concentration of C1 INH + “Trigger” = Increased Probability of an AE Attack “Vulnerable Period” 2) Decrease the “Vulnerable Period”

  106. Slide 106: Treating vs Preventing an AE Attack

    Time (hr) Dose administered IV SC It’s Important to Point Out That Treating An AE Attack is Different Than Preventing One. *For illustration purposes only U/mL 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0 50 100 150 200 250 300 350 400 450

  107. Slide 107: Decrease the Vulnerable Period

    “Vulnerable Period” Time (hr) IV SC Preventing AE Attacks.Decrease the “Vulnerable Period” *For illustration purposes only Infection Trauma, other Insufficient Concentration of C1 INH + “Trigger” U/mL 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0 50 100 150 200 250 300 350 400 450

  108. Slide 108: Inhibition of auto-activation

    Time (hr) “Ain’t It Like Most People, I’m No Different. We Love To Talk On Things We Don’t Know About.” The Avett Brothers Ziccardi, 1982; Windfuhr, 2005 Inhibition of auto-activation Prevention of AE attacks Spath, 1984; Cicardi, 1998 & unpublished; Hack, 2012 Abate an ongoing AE attack Hack et al.

  109. Slide 109: Challenges of IV to SC

    Going from IV to SC Presents a Few Challenges. Sc injection Molecules > 16kDa % Deposition at injection site % Peripheral lymphatic uptake Uptake of < 16 kDa Molecules into capillaries Degradation? Binding? Transport to central lymphatic ducts IV injection Thoracic blood vessel Impacted by: Protein

  110. Slide 110: Methods to Address Challenges of SC Delivery

    Potential Methods to Address The Challenges of SC Delivery “Shock and awe” dosing Optimize delivery system PH20 Micro-needle administration Optimize formulation

  111. Slide 111: Significant Work Already Completed

    We’ve Done A Significant Amount of Work Already. *completed Study 100* Single-dose Cinryze SC Healthy subject Functional C1-INH Change From Baseline (%) Concentration Functional C1 INH Activity (U/mL) 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 50 100 150 200 250 300 350 400 450 Time (h) Mean IV (N=25) Mean SC 10

  112. Slide 112: Cinryze SC End-of-Phase 2 Meeting with FDA

    CINRYZE SC- EoPh2 Meeting with FDA FDA provided feedback on completed studies, proposed study design, endpoints, safety database and commented on their desire for additional dose-ranging data *completed Cinryze SC Program April 2011 EoPh2 Meeting* Study 100* Study 200* Single-dose Cinyrze SC Healthy

  113. Slide 113: Cinryze SC Program Timeline

    WWVD??? *completed ; ^IND enabling Cinryze SC Program EoPh2 Meeting* April 2011 VPHM/ HALO Collaboration Initiated* May 2011 CINRYZE + PH20 Multi-dose in HAE pt Study 204* CINRYZE SC

  114. Slide 114: Study 200/204 HAE Subjects: C1 INH Functional

    CINRYZE Study 200/204 HAE-Subjects: C1 INH Functional 1000 U Time (hr) Dose administered U/mL 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0 50 100 150 200 250 300 350 400 450 IV SC 1000 SC 1000 + PH20

  115. Slide 115: Which of These Things Is Not Like The Other?

    Which of These Things Is Not Like The Other?

  116. Slide 116: Study 200/204 Additional Lessons Learned

    CINRYZE Study 200/204 HAE-Subjects: Additional Lessons Learned CINRYZE SC ALONE CINRYZE + PH20 C1INH Function Plasma Concentration C1INH Function Plasma Concentration

  117. Slide 117: Cinryze + rHuPH20 Program was Prioritized

    CINRYZE + rHuPH20 Program was Prioritized Addition of rHuPH20 has the potential to improve: CINRYZE PK/PD profile Increased dispersion and absorption Reduces intra/intersubject variability Achieves physiologically relevant plasma concentrations associated with protection against HAE attacks Tolerabi

  118. Slide 118: Baxter Complete Response Letter, July 2012

    And Then On One Sunny Day in July 2012. Baxter receives Complete Response Letter from FDA for their HyQvia program Implications for the CINRYZE + PH20 program “Temporary clinical hold” on all clinical studies using the co-administration of hyaluorinidase for ‘life-span’ products within CBER while da

  119. Slide 119: ViroPharma and Halozyme Clinical Development Update

    And As You Probably Heard Earlier This Morning. VIROPHARMA AND HALOZYME PROVIDE UPDATE ON CLINICAL DEVELOPMENT OF SUBCUTANEOUS CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) WITH RECOMBINANT HUMAN HYALURONIDASE (rHuPH20) Exton, PA, September 21, 2012—Viropharma Incorporated (Nasdaq: VPHM) and Halozyme The

  120. Slide 120: Cinryze SC Program: Next Steps

    CINRYZE SC Program: Next Steps “Things turn out best for the people who make the best of the way things turn out.” -John Wooden

  121. Slide 121: Cinryze SC Programs Next Steps

    CINRYZE SC Programs Next Steps: The Best Offense is a Great Defense “Shock and awe” dosing Optimize delivery system PH20 Optimize formulation

  122. Slide 122: Cinryze SC Programs: Next Steps

    CINRYZE SC Programs: Next Steps Dose-ranging Long-term Prevention Study 30x Phase 1/2 Phase 3 Multi-dose in Healthy subject Study 102** CINRYZE + PH20 Single-dose in Healthy subject Study 101* Multi-dose in HAE pt Study 204^* Multi-dose in HAE pt Study 206** Long-term Prevention Study 300 *completed

  123. Slide 123: Acknowledgements

    Acknowledgements Collaborators Patients HAE Associations Clinicians and investigators Sanquin Halozyme ViroPharma Cinryze Team 125

  124. Slide 124: An Update on Maribavir

    An Update on Maribavir Stephen Villano, MD Vice President, Clinical Research & Development 126

  125. Slide 125: Human Cytomegalovirus (CMV)

    Human Cytomegalovirus (CMV) Beta herpesvirus Large genome Infection becomes latent 60-100% adults infected Close interaction with the immune system Can be fatal if over- immunocompromised Reddehase 2006 UL97 UL54 TRL TRS IRL IRS US UL 127

  126. Slide 126: CMV Manifestations

    CMV Manifestations Direct effects: CMV symptomatic viremia CMV invasive organ disease Indirect effects: Risk of other opportunistic infections Stem cell transplant (SCT): risk of graft versus host disease (GVHD) Solid organ transplant (SOT): risk of graft organ rejection / graft loss Survival disadv

  127. Slide 127: Current Anti-CMV Drugs and Toxicity

    Renal Toxicity, Seizures Drug Form. CMV Indication Toxicity ganciclovir IV Treatment of CMV retinitis in immunocompromised patientsPrevention of CMV disease in transplant recipients at risk Bone marrow suppression, carcinogenic, teratogenic ganciclovir PO Prevention of CMV disease in solid organ tra

  128. Slide 128: Maribavir: A Novel Anti-Viral Drug

    Chemical class: benzimidazole Orally bioavailable Unique mechanism: Inhibit viral encapsidation Inhibit nuclear egress of viral particles Unlike other anti-CMV agents, maribavir does not affect the UL54 CMV DNA polymerase Maribavir has in vitro activity against strains of CMV resistant to other anti

  129. Slide 129: Mechanism of Action

    Mechanism of Action UL97 (CMV) DNA elongation DNA packaging Capsid egress Protein kinase GCV UL97 (CMV) GCV-P UL54 Viral DNA replication Chain termination DNA polymerase Protein kinase Ganciclovir Maribavir

  130. Slide 130: Maribavir for CMV Treatment

    US Emergency-IND(E-IND) a EUName Patient Program (NPP) b Population studied Resistant / Refractory CMV Resistant / Refractory CMV Number with data 6 9 SCT / SOT 1 / 5 3 / 6 Known resistance mutations to GCV or FOS 4 (67%) 6 (67%) Virologic response CMV Undetectable:4 (67%) CMV ? ^1.5 log or undetect

  131. Slide 131: Phase 2 Dose Ranging Studies in Transplant Recipients

    Phase 2 Dose Ranging Studies in Transplant Recipients EU: first line treatment of CMV viremia US: treatment of resistant/ refractory CMV disease Study Number 1263-203 1263-202 Regimens MBV 400 mg BID MBV 400 mg BID Regimens MBV 800 mg BID MBV 800 mg BID Regimens MBV 1200 mg BID MBV 1200 mg BID Regim

  132. Slide 132: EU Phase 2 Study Preliminary Virology Data

    EU Phase 2 Study (1263-203) Preliminary Virology Data Number with data available through Week 2 10 SCT / SOT 8 / 2 Virologic response CMV Undetectable:10 / 10 (100%) Quant. Limit 200 copies/mL NOTE: shown are interim data only; study is ongoing 134

  133. Slide 133: Maribavir: Next Steps

    Maribavir: Next Steps On-going Phase 2 dose ranging studies in transplant recipients Phase 1 studies / higher doses (in concert with dose finding) Discussion with Regulatory agencies re: pivotal design Pivotal Studies ? NDA EU: first line treatment of CMV viremia US: treatment of resistant/ refracto

  134. Slide 134: Transplantation: Numbers

    Transplantation: Numbers Total transplants per year(all ages) US EU SCT (Allogeneic) 7,012 a 13,345 b SOT 28, 537 c 30,448 d Kidney 16,813—Liver 6,342—Heart 2,322—Lung 1,822—Other 1,238—a) CIBMTR 2009; b) EBMT 2010; c) OPTN 2011; d) estimate from multiple registries 136

  135. Slide 135: Patient Population Assumptions

    Patient Population Assumptions 100 patients 25% MBV 60 Viremic 70% responding 14 pts. 31 pts. 12 patients 90% switch to MBV 16 patients 50% intolerant, switch to MBV 30% not responding 45 pts. 75% (v)GCV SOT: 100 patients 25% MBV 40 Viremic 70% responding 9 pts. 21 pts. 8 patients 90% switch to MBV

  136. Slide 136: Conclusions

    Conclusions CMV continues to be the most important transplant infection, with direct and indirect adverse effects Current therapy for CMV is limited by toxicity that can restrict use Maribavir, at higher doses, has been shown to decrease viral load in preliminary evaluations of CMV-infected transpla

  137. Slide 137: VP-20621 Non-toxigenic C. difficile

    VP-20621 Non-toxigenic C. difficile Colin Broom, MD Vice President, Chief Scientific Officer 139

  138. Slide 138: VP-20621 – For the Prevention of Recurrence of CDI

    VP-20621 – For the Prevention of Recurrence of C. difficile Infection (CDI) CDI – An Overview The Problem of CDI Recurrence Clinical Study Results to Date Summary & Conclusions 140 For internal use only—CONFIDENTIAL

  139. Slide 139: CDI Overview

    CDI Overview 141 Spore-forming, anaerobic, gram-positive bacterium Causes gastrointestinal infections resulting in diarrhea and colitis Severity ranges from mild colitis to toxic megacolon and death Leading cause of healthcare-associated infectious diarrhea in US Rivals methicillin-resistant Staphyl

  140. Slide 140: Treatment is Effective but has Limitations

    Treatment is Effective but has Limitations 142 Standard of care is oral metronidazole or vancomycin, with fidaxomicin a recent introduction All are associated with recurrence No approved therapy for prevention of recurrence Current practice: Repeated antibiotic therapy Other non-approved agents or p

  141. Slide 141: Recurrence Rate Increases after First CDI Episode

    Recurrence Rate Increases after First CDI Episode 20% 45% 65% 1. Aslam S, et al. Lancet Infect Dis. 2005;5:549-557. 2. McFarland LV, et al. Am J Gastroenterol. 2002:97:1769-1775. 3. McFarland LV, et al. JAMA. 1994;271:1913-1918. 0% 10% 20% 30% 40% 50% 60% 70% After first episode 1 After first recurr

  142. Slide 142: Unmet Medical Need is Recognized

    Unmet Medical Need is Recognized CDI Competitive Landscape Antibiotics with narrower spectrum May reduce but will not prevent recurrence No difference in recurrence rate with the hyper-virulent BI/NAP1/027 strain Monoclonal antibodies to Toxin A & B Vaccine approach to prevention 144

  143. Slide 143: VP-20621 May Address this Unmet Medical Need

    VP-20621 May Address this Unmet Medical Need VP-20621 is a formulation of spores of a specific, naturally occurring non-toxigenic strain of C. difficile Can colonize the GI tract of susceptible individuals Colonization may prevent CDI, based on animal and epidemiological studies 145

  144. Slide 144: NTCD Phase 1 Study Design

    NTCD Phase 1 Study Design Safety and Tolerability of an Oral Suspension of VP-20621, Spores of a Non-Toxigenic C. difficile Strain, in Healthy Older Subjects Well tolerated with single and repeat doses: 1x104, 1x106, or 1x108 spores (or matching placebo) Colonization of all subjects pre-treated with

  145. Slide 145: 20621-200 Phase 2 Study

    20621-200 A Phase 2 Randomized, Double-Blind, Placebo- Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) in Adults Previously Treated for CDI 147

  146. Slide 146: 20621-200 Study Design

    Screening (Up to 28 days) Study Drug Administration (14 Days) Follow-Up Vanco or Metro 10-21 days; CDI Resolves CDI Onset Randomize to start study drug after end of Vanco/Metro 107 QD x 7d 107 QD x 14d 104 QD x 7d F/U to Week 26 Placebo Placebo Placebo Key timepoint for efficacy assessments 20621-20

  147. Slide 147: Study Objectives

    Study Objectives Evaluate the safety and tolerability of VP-20621 Determine colonization of the GI tract in patients treated for CDI Select a dosing regimen based on colonization data Preliminary information on the prevention of recurrence

  148. Slide 148: Achievement of Study Objectives

    Achievement of Study Objectives Interim data in 106 of target 240 patients Well tolerated, no safety issues identified Ability to colonize clearly demonstrated Good data on dose and duration of therapy Limited but informative data on disease recurrence

  149. Slide 149: 20621-200: Interim Subject Characteristics

    Interim N 106 Age (yrs) Median (range) 59 (18-94) ^65 39% Female / Male 63% / 37% Inpatient / Outpatient 20% / 80% Primary CDI 81% Initial CDI Treatment Metronidazole 61% Oral vancomycin 24% Both 15% 20621-200: Interim data subject characteristics

  150. Slide 150: Preliminary C. difficile Stool Culture Data

    Based on 106-subject interim analysis 20621-200 Preliminary C. difficile Stool Culture Data Cx + Tox+ Cx+ Tox—(NTCD) Placebo (n=20-22 subjects per visit) 100% 80% 60% 40% 20% 0% D1 D8 D15 W3 W6 0% 0% 0% 0% 15% 18% 62% 67% 70% 40% Study Visit NTCD 104 x 7d (n=27-28 subjects per visit) 100% 80% 60% 40

  151. Slide 151: 20621-200 Preliminary CDI Recurrence Data

    20621-200 Preliminary CDI recurrence data Based on 106-subject interim analysis PBO 104 x 7d 107 x 7d 107 x 14d ITT-S Subjects 23 29 26 28 Subjects with: CDI recurrence No recurrence occurred in patients colonized with VP20621

  152. Slide 152: Summary and Conclusions from Interim Data

    Summary and Conclusions from Interim Data VP-20621 was well tolerated with no safety issues identified Limited recurrence data has been informative Eight of the 10 patients with recurrent disease in the VP-20621 treated groups had a toxigenic strain at Day 1 and/or Day 8 suggesting that earlier trea

  153. Slide 153: Financial Update / Guidance

    Financial Update / Guidance Charles Rowland Chief Financial Officer 155 This presentation includes non-GAAP forecasted gross margins. We believe that presentation of forecasted non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors.

  154. Slide 154: ViroPharma Outlook

    ViroPharma Outlook 156 Significant short to midterm sales growth Growth from existing products Geographic expansion Not pipeline dependent Efficient operating model requiring lower R&D and SG&A spend Generating greater GAAP and Non-GAAP returns Net Income EPS Efficient use of Cash Lower risk busines

  155. Slide 155: Product Outlook

    Product Outlook Estimate of Commercial Potential Cinryze® – HAE IV only US & Europe Sustained growth in demand—driven by consistent patient adds and dosing rates >$700M Europe – Buccolam,® Cinryze, Plenadren®(Cinryze also included in guidance above) 2012 and 2013 are key launch years for all three E

  156. Slide 156: Marketed Products Expected to Contribute ~20% CAGR

    Marketed Products Expected to Contribute Approximately 20% CAGR through 2015 158 $700—$800 $0 $250 $500 $750 $1,000 2012 2015 Guidance Range Net Sales Net Sales ($ millions)

  157. Slide 157: Europe Expected to Become a Larger Share of the Business

    Europe Expected to Become a Larger Share of the Business and a Significant Contributor to Top Line Growth 159 2012 Sales Breakdown 2015 Sales Breakdown EU Sales 5% US Sales 95% Row Sales<1% EU Sales ~30% US Sales ~70%

  158. Slide 158: Current Pipeline

    Current Pipeline 160 2012 2013 2014 2015 2016 2017 Formulation Development C1 INH – SC Expansion Plenadren – US Pipeline Maribavir (CMV) VP 20629 (Friedreich’s Ataxia) VP 20261 (Rec. C-Diff) Oral Budesonide (EoE) Cinryze (AMR) C1 Esterase (New Uses) C1 Recombinant Phase 2 Phase 3 Approval Path forwa

  159. Slide 159: Pipeline Provides Commercial Potential Upside

    ViroPharma Pipeline Provides Commercial Potential Upside 161 Pipeline opportunities primarily focused on orphan indications Potential to contribute meaningfully to longer-term revenue growth Other components of upside: Plenadren US VP-20629 (Friedreich’s Ataxia) Oral Budesonide (EoE) Recombinant C1-

  160. Slide 160: Disciplined Expense Management

    Disciplined Expense Management with Targeted Investments to Drive Growth 162 Gross Margin Ex-Vancocin margins have remained consistentExpected to improve slightly in near-term Streamlined operating model requiring lower R&D and SG&A spend R&D Spend is focused on development onlyTargeted toward futur

  161. Slide 161: Revenue Drivers and Expense Management Drive Earnings Power

    Revenue Drivers and Expense Management Translates to Significant Earnings Power Tangible near-term revenue growth Cinryze® new patient growth and acceleration in Europe Plenadren® and Buccolam® launch execution Targeting future lower operating costs and lower R&D spend due to development focus Inves

  162. Slide 162: Disciplined and Efficient Capital Management

    Commitment to Disciplined and Efficient Capital Management ViroPharma is committed to being good stewards of investor capital $82M share repurchase in Q3 2012 (3.1m Shares) Strong near-term liquidity with $390M in cash and $200M in revolver capacity Returned $323M to shareholders in 2011 – 2012 (14.

  163. Slide 163: Our Deal History

    Our Deal History 165 ($ millions) Upfront Payment Milestones Total Deal Value Peak Sales Potential Marketed Products Vancocin 116.0 51.1 167.1 289.0 Cinryze 453.1 92.1 545.2 >700.0 Plenadren 35.0 88.0 123.0 >200.0 * Buccolam 14.5 15.8 30.3 90.0 Pipeline Halozyme 9.0 47.0 56.0 Meritage 12.5 252.4 264

  164. Slide 164: 2015 Outlook

    2015 Outlook A Growth Story 166 Category Estimate of Future Opportunity ($ in millions) Total Company Net Sales $700M—$800M R&D and SG&A Combined $270M—$320M Effective Tax Rate ~32% Earnings Growth Differentiated

  165. Slide 165: Conclusions

    Conclusions Significant short to midterm sales growth Growth from existing products Geographic expansion Not pipeline dependent Efficient operating model requiring lower R&D and SG&A spend Generating greater GAAP and Non-GAAP returns Net Income EPS Efficient use of Cash Lower risk business developme

  166. Slide 166: Quote: Ralph Waldo Emerson

    Do not go where the path may lead, go instead where there is no path and leave a trail. Ralph Waldo Emerson

  167. Slide 167: Questions & Answers

    ——| Avligrunrn Questions & Answers 169

ViroPharma — Investor Day (September 2012) on 6ix